OTC:RGBP
Regen BioPharma Inc
A clinical-stage biopharmaceutical developer advancing novel oncology and immunology therapeutic candidates to address unmet medical needs in cancer care.
Key Metrics
Investment Thesis
Bull Case
Early-stage biotech investors may view Regen BioPharma as a high-potential speculative play if any of its drug candidates successfully advance to late-stage trials or receive regulatory approval. The company's substantial cash reserves relative to its current burn rate suggest adequate runway to pursue critical development milestones without immediate dilution. If the company secures significant strategic partnerships or licensing deals, it could transform its revenue profile and valuation multiple significantly.
Bear Case
The negative net income of $1.3 million and persistent operating losses indicate that the company is not yet generating sustainable commercial cash flow to support growth independently. With current liabilities exceeding assets by a wide margin relative to equity, the balance sheet shows significant leverage in terms of accumulated deficits rather than debt. Investors should exercise caution given the high probability of further dilution and the inherent risks associated with developing multiple early-stage therapeutic candidates simultaneously.
About Regen BioPharma Inc
Regen BioPharma Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutic candidates, primarily within the oncology and immunology sectors. The company leverages proprietary technology platforms to advance early-stage drug candidates through preclinical and clinical development stages. Currently, the company operates with minimal revenue generation while maintaining significant cash reserves to fund its research and development pipeline.
Analysis
Management Discussion
The company reported a net loss of $1.3 million for the most recent period, consistent with its status as a clinical-stage entity investing heavily in R&D while generating negligible revenue. Cash flow from operations was negative at -$383,591, though financing activities provided significant inflows totaling $452,430, likely through equity issuances or grants to extend runway. Despite the operational burn, the company maintains a healthy cash position of approximately $69,555 and has managed working capital changes effectively to preserve liquidity.
Industry Overview
The biopharmaceutical industry is characterized by long development cycles, high capital requirements, and a binary outcome where successful drug candidates can generate substantial value while failures result in total loss. Regulatory scrutiny from agencies like the FDA or EMA is intense, requiring extensive clinical data to prove safety and efficacy before market entry. Recent trends favor targeted therapies and personalized medicine, driving competition among companies pursuing novel mechanisms of action in oncology.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | $126.6K | $236.6K | $236.6K |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $126.6K | $236.6K | $236.6K |
| Operating Expenses | $813.5K | $653.8K | $575.1K |
| Operating Income | $-687.0K | $-417.2K | $-338.5K |
| R&D | $212.3K | $153.7K | $11.7K |
| G&A | $45.0K | $58.9K | $75.1K |
| Stock-Based Comp | — | $13.0K | — |
| Other OpEx | $556.2K | $441.2K | $488.3K |
| Non-Operating Income | $0 | $-251.0K | $-936.0K |
| Interest Expense | $58.6K | — | — |
| Pre-Tax Income | $-687.0K | $-668.3K | $-1.3M |
| Income Tax | $-1.8M | $0 | $0 |
| Continuing Ops | $1.2M | $-668.3K | $-1.3M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $1.2M | $-668.3K | $-1.3M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $1.2M | $-668.3K | $-1.3M |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Current Assets | $131.0K | $143.4K | $274.6K |
| Cash & Equivalents | — | $716 | $69.6K |
| Accounts Receivable | $0 | $94.9K | $204.9K |
| Other Current Assets | $131.0K | $47.8K | $200 |
| Long-Term Assets | $222.6K | $17.7K | $0 |
| Total Assets | $353.6K | $161.1K | $274.6K |
| Current Liabilities | $5.3M | $5.4M | $6.6M |
| Accounts Payable | $29.7K | $29.7K | $1.7K |
| Other Current Liab | $5.3M | $3.7M | $4.7M |
| Long-Term Liabilities | $149.6K | $0 | $0 |
| Total Liabilities | $5.5M | $5.4M | $6.6M |
| Shareholders' Equity | $-5.1M | $-5.2M | $-6.3M |
| Paid-In Capital | $13.9M | $15.4M | $15.6M |
| Retained Earnings | $-19.7M | $-20.4M | $-21.7M |
| AOCI | — | $-204.8K | $-222.6K |
| Total L&E | $353.6K | $161.1K | $274.6K |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Net Income (CFO) | $1.2M | $-668.3K | $-1.3M |
| Non-Cash Adjustments | $1.1M | $-94.2K | $55.4K |
| Working Capital Changes | $-2.5M | $10.9K | $835.5K |
| Cash from Operations | $-173.9K | $-751.5K | $-383.6K |
| Cash from Investing | $0 | $0 | $0 |
| Cash from Financing | $243.8K | $631.2K | $452.4K |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $69.8K | $-120.3K | $68.8K |
| Beginning Cash | $51.2K | $121.0K | $716 |
| Ending Cash | $121.0K | $716 | $69.6K |
Frequently Asked Questions
How does Regen BioPharma Inc make money?
The company's financial profile indicates a focus on early-stage drug discovery and development, with revenue derived from strategic partnerships, licensing agreements, or limited commercial sales of investigational products. Operations are characterized by high operating expenses driven by research and development activities rather than established product line sales. The balance sheet reflects an asset-light model typical of biotech firms prior to commercialization.
What are the main risks for RGBP?
The company faces significant financial risk due to its negative cash flow from operations and a substantial accumulated deficit, relying heavily on external capital raises to fund activities. As a pre-revenue biopharmaceutical firm, the business model carries high failure risk associated with clinical trial outcomes and regulatory approval uncertainties. Dilution of existing shareholders is a likely outcome if the company must issue additional equity to sustain its burn rate and funding needs. Limited liquidity and reliance on a single market segment or pipeline assets increase vulnerability to adverse events.
What is RGBP's competitive advantage?
Regen BioPharma possesses a proprietary technology platform designed to accelerate the discovery and optimization of novel therapeutic compounds. The company maintains a specialized team of scientists and clinicians focused on advancing its pipeline through critical clinical milestones. Strategic collaborations with academic institutions or industry partners may provide access to unique biological targets and shared development costs.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.